NEW YORK, October 2, 2013 /PRNewswire/ --
Editor Note: For more information about this relea se, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Covidien plc (NYSE: COV), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), ICON plc (NASDAQ: ICLR), Novadaq Technologies Inc. (NASDAQ: NVDQ), and Antares Pharma Inc. (NASDAQ: ATRS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Covidien plc Research ReportOn September 19, 2013, Covidien plc (Covidien) announced that its Board of Directors has authorized a 23% increase in its quarterly dividend rate. The revised dividend will be $0.32 per ordinary share compared to the previous $0.26 per ordinary share. "This increase reflects our good performance to date in 2013 and our confidence in further growth," said José E. Almeida, Chairman, President and CEO. "We remain committed to using our strong cash flow to fund business expansion, while returning at least 50% of our free cash flow to shareholders through dividends and share repurchases. In the last twelve months, we have exceeded this target, returning over 125% of our free cash flow to shareholders." The Company reported that quarterly dividend is payable on November 5, 2013, to shareholders of record as on October 10, 2013. The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/a14c_COV] -- Ironwood Pharmaceuticals Inc. Research Report On September 10, 2013, Ironwood Pharmaceuticals, Inc. (Ironwood) and AstraZeneca Pharmaceuticals Co., Ltd. (AstraZeneca) announced the beginning of a Phase III clinical trial in China of linaclotide for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). "IBS-C is estimated to affect at least 13 million adults in China, causing hallmark symptoms such as abdominal pain and constipation," said David Snow, President of AstraZeneca China. "If approved in China, linaclotide could be the first prescription treatment specifically for IBS-C and could then help address an unmet need for millions of suffering patients." Ironwood and AstraZeneca anticipate the availability of top-line data in H1 2015 and, if approved by the China Food and Drug Administration(CFDA), anticipate that linaclotide could be commercialized in China in 2017. The Full Research Report on Ironwood Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/dbc4_IRWD] --